文献速递肺外科

I期非小细胞肺癌:肺叶切除与亚肺叶切除的远期结果——波兰国家肺癌登记研究

Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

该回顾性研究基于波兰国家肺癌登记(2007–2013年)6905例I期NSCLC手术患者,经倾向评分匹配比较肺叶切除、肺段切除与楔形切除各231例的总体生存。结果显示楔形切除的3年和5年生存率显著低于肺叶切除和肺段切除,而肺叶切除与肺段切除之间无显著差异。肺段切除可考虑作为肺叶切除的替代,但楔形切除不宜。

要点

  • 楔形切除的5年生存率显著低于肺段切除和肺叶切除。
  • 肺叶切除与肺段切除的5年生存率无显著差异。
  • 肺段切除可考虑作为I期NSCLC肺叶切除的替代术式。

核心结论

  • 楔形切除相比肺段切除和肺叶切除与显著更低的3年和5年生存率相关。
  • 肺叶切除与肺段切除之间3年或5年生存率无显著差异。
  • 肺段切除可考虑作为I期NSCLC肺叶切除的替代,楔形切除则不宜。

研究设计与样本

  • 采用倾向评分匹配分析比较肺叶切除、肺段切除和楔形切除三组,每组各231例。

主要发现

  • 在未匹配和匹配患者组中,肺叶切除和肺段切除相比楔形切除在总体生存上均有显著获益(log-rank P < 0.001 和 P = 0.001)。
  • Cox比例风险比显示肺段切除和肺叶切除相比楔形切除分别为0.54(95%CI: 0.37-0.77)和0.44(95%CI: 0.38-0.50),表明生存显著改善。
  • 肺叶切除5年生存率为79.1%(95%CI: 77.7-80.4%),肺段切除为78.3%(95%CI: 70.6-86.0%),两者无差异。
  • 楔形切除5年生存率为58.1%(95%CI: 53.6-62.5%),显著低于肺段切除(78.3%; 95%CI: 70.6-86.0%)和肺叶切除(79.1%; 95%CI: 77.7-80.5%)。
  • 30天死亡率:肺叶切除1.6%,肺段切除2.6%,楔形切除1.4%。

关键数值与推荐

  • 肺叶切除5年生存率79.1%(95%CI: 77.7-80.4%),肺段切除78.3%(95%CI: 70.6-86.0%),楔形切除58.1%(95%CI: 53.6-62.5%)。
  • 肺段切除对比楔形切除的Cox风险比为0.54(95%CI: 0.37-0.77),肺叶切除对比楔形切除为0.44(95%CI: 0.38-0.50)。
  • 30天死亡率:肺叶切除1.6%,肺段切除2.6%,楔形切除1.4%。

临床怎么用

  • 对于I期NSCLC,肺段切除可考虑作为肺叶切除的替代术式。
  • 楔形切除不宜作为I期NSCLC的推荐术式,因其与显著更低的远期生存相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anatomical lobar resection and mediastinal lymphadenectomy remain the standard for the treatment of early stage non-small-cell lung cancer (NSCLC) and are preferred over procedures such as segmentectomy or wedge resection. However, there is an ongoing debate concerning the influence of the extent of the resection on overall survival. The aim of this article was to assess the overall survival for different types of resection for Stage I NSCLC. METHODS: We performed a retrospective analysis of the results of the surgical treatment of Stage I NSCLC. Between 1 January 2007 and 31 December 2013, the data from 6905 patients who underwent Stage I NSCLC operations were collected in the Polish National Lung Cancer Registry (PNLCR) and overall survival was assessed. A propensity score-matched analysis was used to compare 3 groups of patients, each consisting of 231 patients who underwent lobectomy, segmentectomy, or wedge resection. RESULTS: In the unmatched and matched patient groups, lobectomy and segmentectomy were associated with a significant benefit compared to wedge resection regarding overall survival (log-rank P < 0.001 and P = 0.001). The Cox proportional hazard ratio comparing segmentectomy and lobectomy to wedge resection was 0.54 [95% confidence interval (CI): 0.37-0.77) and 0.44 (95% CI: 0.38-0.50), respectively, indicating a significant improvement in survival. There was no difference in the 5-year survival of patients after lobectomy (79.1%; 95% CI: 77.7-80.4%) or segmentectomy (78.3%; 95% CI: 70.6-86.0%). The 30-day mortality rate was 1.6, 2.6 and 1.4% for lobectomy, segmentectomy and wedge resection, respectively. Wedge resection was associated with a significantly lower 5-year survival rate (58.1%; 95% CI: 53.6-62.5%) compared to segmentectomy (78.3%; 95% CI: 70.6-86.0%) and lobectomy (79.1%; 95% CI: 77.7-80.5%). The propensity score matched analysis confirmed most of the results of the comparisons of unmatched study groups. CONCLUSIONS: Wedge resection was associated with significantly lower 3-year and 5-year survival rates compared to the other methods of resection. There was no significant difference in 3-year or 5-year survival rates between lobectomy and segmentectomy. Segmentectomy, but not wedge resection, could be considered an alternative to lobectomy in the treatment of patients with Stage I NSCLC.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Dziedzic R, Zurek W, Marjanski T, et al. Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg. 2017. PMID: 28402455. doi:10.1093/ejcts/ezx092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。